利妥昔单抗(Rituximab) - 药物靶点：CD20_在研适应症：心脏移植排斥反应，肝移植排斥反应，肺移植排斥反应_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

IDEC-C2B8-anti-CD20、Ristova、Rituximab (Genetical Recombination)

+ [14]

靶点

CD20

作用机制

CD20抑制剂(B淋巴细胞抗原CD20抑制剂)、ADCC(抗体依赖的细胞毒作用)、CD20定向的溶细胞作用

治疗领域

肿瘤免疫系统疾病感染+ [11]

在研适应症

心脏移植排斥反应肝移植排斥反应肺移植排斥反应+ [108]

非在研适应症

急性移植物抗宿主病成人急性髓性白血病淋巴母细胞淋巴瘤+ [123]

原研机构

Genentech, Inc.

在研机构

Genentech, Inc.Genmab, Inc.

National Cancer Institute

+ [26]

非在研机构

Astex Pharmaceuticals, Inc.

Biogen, Inc.

Takeda Pharmaceutical Co., Ltd.

+ [16]

最高研发阶段批准上市

首次获批日期

美国 (1997-11-26),

非霍奇金淋巴瘤

最高研发阶段(中国)批准上市

特殊审评孤儿药 (欧盟)、孤儿药 (日本)、孤儿药 (美国)

登录后查看时间轴

序列信息

Sequence Code 27145L

来源: *****

Sequence Code 83181H

来源: *****

关联

2,410

项与利妥昔单抗相关的临床试验

NCT06522386 / Not yet recruiting临床2期IIT

GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma

Primary Objectives:
To estimate the percent of participants who achieve a best response of complete response by the end of the PRV combination therapy in the induction therapy phase in patients with previously untreated MCL.

开始日期2025-12-01

申办/合作机构

The University of Texas MD Anderson Cancer Center

NCT04480450 / Not yet recruiting临床2期IIT

Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy: A Phase II Study

CIDP is a heterogeneous disease with variable responses to therapy. Recently, a distinctive subgroup of patients with serum autoantibodies to the paranodal proteins contactin and neurofascin have been identified. Although they present with active and serious disease, multiple clinical reports suggest that these patients can be cured with a treatment that depletes B cells and presumably eliminates pathogenic autoantibodies. However, beyond that subgroup of CIDP patients, which CIDP patients might benefit from Rituximab and B cell depletion is unknown. This Phase II study will treat 3 homogenous groups of 16 CIDP patients each with Rituximab in order to determine if there are subgroups that can be taken off current medications and put into long-term remission. The results from this study will be used to design a future larger trial. Biomarkers including paranodal antibodies, serum neurofilament light chains, anti-ganglioside antibodies will be obtained in order to learn about disease pathogenesis and possibly target therapy

开始日期2025-07-01

申办/合作机构

University of Kansas

NCT06711354 / Not yet recruitingN/AIIT

B-cell Depletion in Offspring to Women With MS and Rituximab Treatment Before or During Pregnancy

The overall aim of the study is to gain knowledge about consequences for the child´s humoral immunosystem in mothers with multiple sclerosis and due to their immunomodulating treatments. Of special interest is when the mother is treated with monoclonal CD20-antibody like rituximab, ocrelizumab and ofatumumab shortly before (within six months prior to conception) and during pregnancy. Specific aims of the study are to:
* Investigate if the humoral immunosystem is fully functioning at birth in children born to mothers with MS
* Investigate if the humoral immunosystem at birth in children born to mothers with MS is influenced by the mothers immunomodulating treatment
* Investigate if monoclonal CD20-antibodies are fully eliminated in women treated with monoclonal CD20-antibodies within 12 months prior to conception.
* Determine if children who have been exposed to monoclonal CD20-antibody in utero have reduced markers of successful B-cell production at birth.
* Investigate the response to the Rota virus vaccine, a life-vaccine that is offered 6 weeks after birth to all children born after September 2019, in children to women treated with rituximab before or during pregnancy.
* Investigate the response to other vaccines (DTP, Polio, HiB, pneumococcus given at 3 and 5 months after birth) the earliest one months after vaccination.
* Investigate the occurrence of infections in the first-year post-partum for the mother and child due to hypogammaglobulinemia, b-cell depletion, and exposure to monoclonal CD20-antibody.
* Investigate if oral exposure to rituximab through mother´s breastmilk is resulting in B-cell reduction in the child.

开始日期2025-06-01

申办/合作机构

Region Stockholm

[+1]

100 项与利妥昔单抗相关的临床结果

登录后查看更多信息

100 项与利妥昔单抗相关的转化医学

登录后查看更多信息

100 项与利妥昔单抗相关的专利（医药）

登录后查看更多信息

27,774

项与利妥昔单抗相关的文献（医药）

2025-04-01·DEN open

Unique endoscopic features of primary biliary diffuse large B‐cell lymphoma: A case report with literature review (with video)

Article

作者: Kameyama, Naohiro ; Ishigami, Keisuke ; Nakase, Hiroshi ; Masaki, Yoshiharu ; Kawakami, Yujiro ; Sugawara, Taro ; Satoh, Shuji ; Nakamura, Tomoya ; Sugita, Shintaro ; Takada, Yumemi

Abstract:

A 67‐year‐old man visited our hospital complaining of dark‐colored urine and upper abdominal pain. Magnetic resonance cholangiopancreatography showed stricture of the distal bile duct, and contrast‐enhanced computed tomography showed irregular thickening of the distal bile duct wall. However, no enlarged lymph nodes, pancreatic tumors, or other neoplastic lesions were apparent around the bile duct. Endoscopic ultrasonography and intraductal ultrasonography showed irregular thickening of the inner hypoechoic layer without the disappearance of the innermost thin hyperechoic layer. On the basis of these findings, we considered that the bile duct lesion was of non‐epithelial origin. Thus, we repeatedly performed bile duct biopsies from the same site under fluoroscopy to obtain a sample of the submucosal tissue. The pathological diagnosis was diffuse large B‐cell lymphoma, and the patient received systemic chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). After six courses of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, positron emission tomography‐computed tomography showed the disappearance of 18‐fluorodeoxyglucose uptake in the bile duct and endoscopic retrograde cholangiography showed improvement of the bile duct stricture. Endoscopic findings and repeated biopsies were useful in making the diagnosis of primary biliary diffuse large B‐cell lymphoma.

2025-02-01·CURRENT DRUG TARGETS

Two Decades Rituximab Therapy in Anti-Neutrophil Cytoplasmic Antibody Associated Vasculitis Mohammad Amin Habibi1, Sajjad Ahmadpour2,*, Javad

Article

作者: Ahmadpour, Sajjad ; Habibi, Mohammad Amin ; Tafaroji, Javad ; Eazi, Seyed Mohammad ; Mohammadpour, Yousef ; Tavakolpour, Soheil ; Mineaie, Poryia

Remission failure and relapse numerate as one of the main problems in patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAVs). The need for new agents that provide effective and safe induction accompanied by sustained remission seems to be urgent in clinical care. The efficacy and safety of rituximab (RTX) for AAVs therapy has been reported in various studies. RTX therapy offers several advantages to treating AAVs patients compared to other therapeutic approaches including reduction of Glucocorticoids (GCs) and conventional Immunosuppressive therapy (IST) usage during both the induction of remission and maintenance phases. This reduction can lead to a lower rate of serious complications making RTX therapy a safer option. It seems that RTX may provide improved clinical outcomes in these patients mediated via B-lymphocyte depletion, Proteinase 3-antineutrophilic cytoplasmic antibody (PR3-ANCA), and myeloperoxidase-antineutrophilic cytoplasmic antibody (MPO-ANCA) titers reduction. In this regard, some uncertainties have been reported to validate the association between such depletion and clinical improvement, as suggested by other sources of autoreactive B cells that did not target with RTX. Due to the prolonged B cell depletion, fixed intervals and adjusted dosage of RTX may be required in patients with AAVs. In this narrative review, we aimed to insight better understand regarding the efficacy of RTX for effective induction and sustained remission in patients with AAVs. It seems that discovering new biomarkers predicting relapse in AAVs patients can lead to future targeted therapy.

2025-02-01·Annals of Diagnostic Pathology

From the archives of MD Anderson Cancer Center: EBV-positive fibrin-associated large B-cell lymphoma in an ovarian leiomyoma with cystic degeneration: A case report and discussion of differential diagnosis

Article

作者: Malpica, Anais ; Medeiros, L Jeffrey ; Marques-Piubelli, Mario L ; Ramalingam, Preetha ; Miranda, Roberto N ; Louro, Luana Santos

Fibrin-associated large B-cell lymphoma (FA-LBCL) is a rare type of lymphoma usually associated with Epstein-Barr virus (EBV) infection. We report a case incidentally detected in a right ovarian mass of a 53-year-old woman. The patient presented with bloating and weight gain over 8 months. Imaging studies showed a 20.7 cm, complex right adnexal mass. Total abdominal hysterectomy and bilateral salpingo-oophorectomy were performed. Macroscopic examination revealed a 25 x 18.5 x 9.5 cm predominantly cystic right ovarian mass with focal solid areas. Microscopically, most of the mass was a leiomyoma with hyaline necrosis and extensive cystic degeneration. In areas, the cyst showed focally necrotic, fibrinous material associated with small aggregates of round and atypical lymphoid cells with prominent karyorrhexis and mitotic activity These large cells were confined within the cystic spaces. Immunohistochemical analysis showed that the atypical cells were positive for CD20, CD30, CD79a and MUM1/IRF4, and were negative for CD3, CD10 and BCL6, supporting B-cell lineage. In situ hybridization for Epstein-Barr virus-encoded RNA (EBER ISH) was also positive in the atypical cells supporting the diagnosis of EBV-positive fibrin-associated large B-cell lymphoma. The patient subsequently received four cycles of chemotherapy using rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). Computed tomography (CT) scan of the neck, chest, abdomen and pelvis 5 months after the last chemotherapy cycle showed no evidence of disease. After a follow-up of 17 months, the patient is alive with no evidence of disease. This report is being used to discuss the salient features of this rare entity and its differential diagnosis.

2,072

项与利妥昔单抗相关的新闻（医药）

2024-12-05

·Business Wire

Foresight Diagnostics Announces Launch of SHORTEN-ctDNA Trial to Evaluate Personalized Treatment Duration in DLBCL Lymphoma Patients

BOULDER, Colo.--( BUSINESS WIRE )--Foresight Diagnostics, a leader in ultra-sensitive minimal residual disease (MRD) detection technology, today announced the launch of SHORTEN-ctDNA, a clinical trial at Columbia University. 1 The study aims to evaluate the ability to utilize Foresight CLARITY™ MRD detection to enable real-time treatment optimization for patients with diffuse large B-cell lymphoma (DLBCL). Currently the standard treatment for newly diagnosed DLBCL requires six cycles of combination rituximab and chemotherapy regardless of individual patient response. This one-size-fits-all approach leaves little room for personalization, potentially exposing patients to unnecessary treatment. The SHORTEN-ctDNA trial will investigate whether patients who achieve early clearance of circulating tumor DNA (ctDNA) can safely receive fewer cycles of chemotherapy while maintaining long-term survival outcomes. "Although PET scans remain our standard tool for monitoring lymphoma treatment, their inconsistent results in identifying active disease limit our ability to make real-time treatment decisions," said David Kurtz, MD, PhD, Chief Medical Officer and Head of Research at Foresight Diagnostics. "Foresight CLARITY's detection of residual disease could be the game-changer we need, potentially allowing us to confidently adjust therapy based on each patient's actual response to treatment with a more dynamic and sensitive tool than imaging." The study will enroll approximately 32 newly diagnosed DLBCL patients. After three cycles of R-CHOP or pola-R-CHP therapy, participants will undergo ctDNA testing. Those with detectable disease (MRD-positive) will continue with rituximab plus chemotherapy for their remaining cycles, while patients who achieve undetectable ctDNA levels (MRD-negative) will de-escalate to rituximab alone for their final two cycles. "Recent evidence suggests many patients achieve very deep remissions earlier in their R-chemo treatment than previously thought," said Hua-Jay Cherng, MD, assistant professor of medicine at Columbia University Vagelos College of Physicians and Surgeons and Principal Investigator of the study. "By using next-generation, ultra-sensitive ctDNA technology, SHORTEN-ctDNA aims to identify these early responders and personalize their treatment strategy, potentially reducing treatment duration and associated toxicity and hopefully getting patients back to their normal lives sooner." More information on the trial may be found here . 1 Full official title of trial: “ S equencing-guided c H emotherapy O ptimization Using R eal- T ime E valuation in N ewly Diagnosed DLBCL With c irculating t umor DNA : SHORTEN-ctDNA." About Foresight Diagnostics Foresight Diagnostics is a privately-held cancer diagnostics company and CLIA-registered laboratory. Its liquid biopsy platform, Foresight CLARITY™, is a novel assay that measures minimal residual disease (MRD) with reported detection limits in parts per million. The improved sensitivity of Foresight CLARITY has the potential to provide actionable information to physicians and biopharmaceutical companies to enable more personalized treatment approaches for patients with solid tumor and hematologic malignancies. For more information, please visit foresight-dx.com and follow us on Twitter and LinkedIn. Foresight CLARITY™ IUO is an investigational device. Limited by United States Law to investigational use.

临床研究

2024-12-05

·Business Wire

Sarah Cannon Research Institute to Showcase Latest Research Insights at the 2024 ASH Annual Meeting & Exposition

NASHVILLE, Tenn.--( BUSINESS WIRE )--Sarah Cannon Research Institute ( SCRI ) announced today that more than 65 abstracts and presentations have been accepted for the 66 th American Society of Hematology (ASH) Annual Meeting & Exposition . Hosted in San Diego, Calif., and online from Dec. 7-10, the event is recognized as the premier global hematology conference, drawing experts and researchers from around the world. SCRI investigators, including physicians from The US Oncology Network and HCA Healthcare Sarah Cannon Transplant & Cellular Therapy Network , will present pioneering research across a range of topics including malignant and non-malignant blood cancers, blood disorders, CAR T-Cell therapy, innovative immunotherapies and real-world outcomes with a specific focus on results between inpatient and outpatient care. “ We look forward to presenting our latest research findings, which include advancements in the treatment of a wide range of hematologic malignancies,” said David Spigel, MD, Chief Scientific Officer for SCRI. “ This year’s presentations are a testament to the collective efforts of investigators across our network, highlighting the power of collaboration in advancing clinical research.” Featured presentations include: Tonya Cox, BSN , HCA Healthcare Sarah Cannon Transplant & Cellular Therapy Network (SCTCTN) , is first author alongside thirteen SCTCTN co-authors on a poster presentation titled, “ Comparison of 15- Vs. 30-Day Remote Patient Monitoring for Outpatient Chimeric Antigen Receptor T-Cell Therapy across a Large Health System” to be shared on Saturday, December 7 at 5:30 p.m. PST. Navneet Majhail, MD, MS, FASTCT, Physician-in-Chief of Blood Cancers for HCA Healthcare Sarah Cannon Cancer Network, and five SCTCTN physicians are co-authors on an oral presentation titled, “ Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above. " The oral presentation takes place on Sunday, December 8 at 9:30 a.m. PST. Minoo Battiwalla, MD, SCRI at TriStar Centennial , is first author alongside eleven SCTCTN co-authors on a poster presentation titled, “ The Patient Journey and Treatment Outcomes Comparing Inpatient Versus Outpatient Axicabtagene Ciloleucel in Non-Hodgkin’s Lymphoma - a Large, Multicenter Study” to be shared on Sunday, December 8 at 6:00 p.m. PST. Jeff P. Sharman, MD, SCRI at Willamette Valley Cancer Institute & Research Center is first author alongside co-author John M. Burke, MD, SCRI at Rocky Mountain Cancer Centers on an oral presentation titled, “ BRUIN CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma." The oral presentation will take place on Monday, December 9 at 3:30 p.m. PST. Haydar Frangoul, MD, SCRI at TriStar Centennial Children's Hospital , is first author on a poster presentation titled, " Durable Clinical Benefits with Exagamglogene Autotemcel for Severe Sickle Cell Disease ” to be shared on Monday, December 9 at 6:00 p.m. PST. A full list of presentations can be found here. About Sarah Cannon Research Institute Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. In 2022, SCRI formed a joint venture with former US Oncology Research to expand clinical trial access across the country. It has conducted more than 800 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. SCRI’s research network brings together more than 1,300 physicians who are actively enrolling patients into clinical trials at more than 250 locations in 24 states across the U.S. Learn more about our research offerings. About The HCA Healthcare Sarah Cannon Transplant & Cellular Therapy Network The HCA Healthcare Sarah Cannon Transplant & Cellular Therapy Network offers adult and pediatric patients convenient and community-based access to treatments for blood cancer and blood and immune-related disorders, including hematopoietic cell transplantation and cellular therapy. Our Network of ten FACT/JACIE accredited transplant centers across the United States and United Kingdom treats more than 1,600 transplant and cellular therapy patients and 2,000 acute leukemia patient admissions annually. Emphasis is placed on providing high-quality research-based care with the opportunity for patients to enroll on innovative clinical trials. For more information about the Sarah Cannon Transplant & Cellular Therapy Network, visit sarahcannon.com. About The US Oncology Network Every day, The US Oncology Network (The Network) helps more than 2,750 independent providers deliver value-based, integrated care to patients — close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The Network provides practices with access to coordinated resources, best business practices, and the experience, infrastructure, and support of McKesson Corporation . This collaboration allows the providers in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. The Network is committed to the success of independent practices, everywhere.

细胞疗法临床3期免疫疗法ASH会议

2024-12-05

·医药魔方Info

罗氏CD20/CD3双抗新适应症申请获FDA受理

12月5日，罗氏宣布，FDA已接受格罗菲妥单抗（glofitamab）的补充生物制品许可申请（sBLA），用于与吉西他滨和奥沙利铂（GemOx方案）联合治疗先前至少接受过一种治疗且不适合自体干细胞移植的复发或难治性弥漫大B细胞淋巴瘤（R/R DLBCL）患者。预计FDA将在2025年7月20日之前做出批准决定。格罗菲妥单抗是一种双特异性抗体，它能够同时靶向T细胞表面的CD3以及B细胞表面的CD20，属于双抗中的T细胞衔接器（TCE）类型。该药采用了一种新颖的2：1结构格式设计，经工程改造，其结构上具有一个与CD3结合的区域和两个与CD20结合的区域。格罗菲妥单抗通过结合CD3和CD20，使T细胞靠近B细胞，并激活T细胞释放穿孔素等细胞杀伤蛋白，从而杀伤致病性B细胞发挥抗肿瘤作用。此前，格罗菲妥单抗已被FDA批准用于治疗既往接受过至少两线系统性治疗的R/R DLBCL或滤泡性淋巴瘤引起的大B细胞淋巴瘤（LBCL）成人患者。此次申请基于III期STARGLO研究，结果显示，与利妥昔单抗联合GemOx（R-GemOx）相比，格罗菲妥单抗联合GemOx显示出具有统计学意义和临床意义的总生存期（OS）改善。在初步分析中（中位随访11.3个月），格罗菲妥单抗将患者的死亡风险降低41%（HR=0.59）。格罗菲妥单抗联合治疗组未达到中位OS，而R-GemOx组的中位OS为9个月。基于此，该药成为了第一个在随机III期研究中显示出DLBCL生存获益的CD20/CD3双特异性抗体。 R/R DLBCL患者的标准二线治疗是高剂量化疗后行干细胞移植，然而，由于年龄或合并症的原因，并非所有患者都适合这种治疗。尽管已有新型疗法问世，但许多患者仍面临治疗障碍。罗氏首席医学官兼全球产品开发负责人 Levi Garraway博士表示：“对于像DLBCL这样的侵袭性淋巴瘤患者，及时干预和有效疗法对于降低疾病进展的风险和改善长期结果至关重要。我们对格罗菲妥单抗组合疗法的总体生存获益感到鼓舞，并希望它能成为那些需要替代疗法的患者的重要治疗选择。” Copyright © 2024 PHARMCUBE. All Rights Reserved. 欢迎转发分享及合理引用，引用时请在显要位置标明文章来源；如需转载，请给微信公众号后台留言或发送消息，并注明公众号名称及ID。免责申明：本微信文章中的信息仅供一般参考之用，不可直接作为决策内容，医药魔方不对任何主体因使用本文内容而导致的任何损失承担责任。精彩预告线上直播 ↑点击扫码，直达直播间↑

临床3期临床结果引进/卖出

100 项与利妥昔单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02994	利妥昔单抗	L01XC02	DB00073

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
心脏移植排斥反应	日本	Zenyaku Kogyo Co., Ltd.	2023-12-22
肝移植排斥反应	日本	Zenyaku Kogyo Co., Ltd.	2023-12-22
肺移植排斥反应	日本	Zenyaku Kogyo Co., Ltd.	2023-12-22
胰腺移植排斥反应	日本	Zenyaku Kogyo Co., Ltd.	2023-12-22
肾移植排斥反应	日本	Zenyaku Kogyo Co., Ltd.	2023-12-22
小肠移植排斥	日本	Zenyaku Kogyo Co., Ltd.	2023-12-22
狼疮性肾炎	日本	Zenyaku Kogyo Co., Ltd.	2023-08-23
视神经脊髓炎	日本	Zenyaku Kogyo Co., Ltd.	2022-06-20
巴西天疱疮	日本	Zenyaku Kogyo Co., Ltd.	2021-12-24
家族性寻常型天疱疮	日本	Zenyaku Kogyo Co., Ltd.	2021-12-24
获得性血栓性血小板减少性紫癜	日本	Zenyaku Kogyo Co., Ltd.	2020-02-21
CD20阳性B细胞慢性淋巴细胞白血病	日本	Zenyaku Kogyo Co., Ltd.	2019-03-26
淋巴细胞白血病	日本	Genentech, Inc.	2019-03-26
淋巴细胞白血病	日本	IDEC Pharmaceuticals Corp.	2019-03-26
慢性特发性血小板减少性紫癜	日本	Zenyaku Kogyo Co., Ltd.	2017-06-26
血小板减少性紫癜	日本	Genentech, Inc.	2017-06-26
血小板减少性紫癜	日本	IDEC Pharmaceuticals Corp.	2017-06-26
肾病综合征	日本	Zenyaku Kogyo Co., Ltd.	2014-08-29
肾病综合征	日本	Genentech, Inc.	2014-08-29
肾病综合征	日本	IDEC Pharmaceuticals Corp.	2014-08-29

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
难治性侵袭性非霍奇金淋巴瘤	临床3期	美国	Hoffmann-La Roche, Inc.	2022-04-25
难治性侵袭性非霍奇金淋巴瘤	临床3期	中国	Hoffmann-La Roche, Inc.	2022-04-25
难治性侵袭性非霍奇金淋巴瘤	临床3期	日本	Hoffmann-La Roche, Inc.	2022-04-25
难治性侵袭性非霍奇金淋巴瘤	临床3期	阿根廷	Hoffmann-La Roche, Inc.	2022-04-25
难治性侵袭性非霍奇金淋巴瘤	临床3期	巴西	Hoffmann-La Roche, Inc.	2022-04-25
难治性侵袭性非霍奇金淋巴瘤	临床3期	加拿大	Hoffmann-La Roche, Inc.	2022-04-25
难治性侵袭性非霍奇金淋巴瘤	临床3期	以色列	Hoffmann-La Roche, Inc.	2022-04-25
难治性侵袭性非霍奇金淋巴瘤	临床3期	墨西哥	Hoffmann-La Roche, Inc.	2022-04-25
难治性侵袭性非霍奇金淋巴瘤	临床3期	新西兰	Hoffmann-La Roche, Inc.	2022-04-25
难治性侵袭性非霍奇金淋巴瘤	临床3期	秘鲁	Hoffmann-La Roche, Inc.	2022-04-25

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04680052 (inMIND, ASH2024) 人工标引	临床3期	滤泡性淋巴瘤	548	Tafasitamab + Lenalidomide + Rituximab	鏇廠壓鹹艱積鬱餘繭膚(繭蓋構憲願蓋膚淵夢積) = 襯鏇鹽積選夢簾繭遞艱鏇壓願壓積網膚艱壓觸 (餘齋憲繭選窪窪襯壓艱 ) 更多	积极	2024-12-10
NCT04680052 (inMIND, ASH2024) 人工标引	临床3期	滤泡性淋巴瘤	548	Placebo + Lenalidomide + Rituximab	鏇廠壓鹹艱積鬱餘繭膚(繭蓋構憲願蓋膚淵夢積) = 網壓製蓋獵製夢製遞廠鏇壓願壓積網膚艱壓觸 (餘齋憲繭選窪窪襯壓艱 ) 更多	积极	2024-12-10
ASH2024 人工标引	临床2期	毛细胞白血病二线	62	Cladribine with Concurrent Rituximab	範餘膚餘醖蓋選鏇壓鹹(選製鏇醖積廠製衊鑰觸) = 遞鑰獵憲艱觸獵鑰築艱醖鬱襯鑰齋鹽齋鬱醖簾 (餘壓淵選繭獵範餘簾鹽 ) 更多	积极	2024-12-09
ASH2024 人工标引	临床2期	毛细胞白血病二线	62	Cladribine Alone	範餘膚餘醖蓋選鏇壓鹹(選製鏇醖積廠製衊鑰觸) = 壓範構鹹鹽艱遞獵範繭醖鬱襯鑰齋鹽齋鬱醖簾 (餘壓淵選繭獵範餘簾鹽 ) 更多	积极	2024-12-09
NCT03620903 (ECWM-2, ASH2024) 人工标引	临床2期	巨球蛋白血症一线	53	Bortezomib+Ibrutinib+Rituximab	獵製壓淵鑰醖夢鬱構築(蓋顧鬱艱選顧憲選憲鹹) = 願選夢獵壓鑰餘選網築窪鏇襯繭簾繭顧鏇鹽遞 (鏇範鏇醖憲簾齋鏇淵顧 ) 更多	积极	2024-12-09
ASH2024 人工标引	临床1期	弥漫性大B细胞淋巴瘤	22	Polatuzumab Vedotin+Zanubrutinib+Rituximab+Lenalidomide	鹽鹹鏇餘顧範餘觸窪願(衊餘構製壓鹽鏇壓壓衊) = 廠夢窪憲鏇蓋鬱齋積製鑰餘願製簾簾顧鏇齋壓 (獵夢醖夢膚壓範餘顧獵 ) 更多	积极	2024-12-09
2085A (ASH2024) 人工标引	临床1期	弥漫性大B细胞淋巴瘤	15	CD19 CAR T-cells with escalating doses of lymphodepletion with or without rituximab	(觸積選憲範艱鑰網製鏇) = 糧艱觸鑰鹹糧壓築製獵積簾鏇淵窪窪壓鬱蓋糧 (鑰積積鬱糧窪築觸簾願 ) 更多	积极	2024-12-07
NCT04663347 (EPCORE NHL-2, ASH2024) 人工标引	临床1/2期	滤泡性淋巴瘤一线	25	Epcoritamab + Bendamustine + Rituximab	(廠鹽蓋蓋餘鏇築顧廠窪) = 積醖簾築鹹獵製觸鹹遞積鏇壓艱餘膚鹽築觸範 (鬱夢鏇構窪顧選積餘範 ) 更多	积极	2024-12-07
ASH2024	N/A	复发性弥漫性大B细胞淋巴瘤	-	R-GemOx	簾廠鏇範膚選淵鹽積構(築範糧網憲淵蓋鹹憲鏇) = 齋壓鏇願鑰願廠鹽壓齋壓醖鬱積醖襯襯製鏇鑰 (醖顧齋遞餘鑰獵糧繭壓, 16‒29) 更多	-	2024-12-07
ASH2024	N/A	套细胞淋巴瘤	-	Acalabrutinib plus bendamustine-rituximab (ABR)	糧構範範網糧襯衊鏇蓋(糧遞網顧遞憲艱鑰觸廠) = 夢膚製選積壓鬱憲蓋鏇築顧繭蓋廠製餘獵衊鹹 (餘觸襯顧鹹夢憲選繭觸 ) 更多	-	2024-12-07
ASH2024	N/A	套细胞淋巴瘤	-	Placebo plus bendamustine-rituximab (PBR)	糧構範範網糧襯衊鏇蓋(糧遞網顧遞憲艱鑰觸廠) = 壓繭窪鹽醖鏇蓋夢鑰齋築顧繭蓋廠製餘獵衊鹹 (餘觸襯顧鹹夢憲選繭觸 ) 更多	-	2024-12-07
NCT02953509 (phase 1/2 trial, Pubmed \| Blood Adv) 人工标引	临床1/2期	非霍奇金淋巴瘤	46	Magrolimabrituximab	(鬱衊鹽遞壓製糧淵夢餘) = 觸簾衊蓋蓋範壓網蓋鹽簾衊鹽範夢積繭廠顧鬱 (構齋夢觸顧積衊艱簾構 ) 更多	积极	2024-11-26
NCT02953509 (Pubmed \| Blood Adv) 人工标引	临床1/2期	弥漫性大B细胞淋巴瘤	132	Magrolimab plrituximabmab	(製膚齋繭製顧膚製衊繭) = 顧範網艱鏇鏇遞膚範鏇餘鏇襯夢鹹鏇糧顧願鑰 (糧醖網窪積糧淵餘網襯 ) 更多	积极	2024-11-26
NCT02953509 (Pubmed \| Blood Adv) 人工标引	临床1/2期	弥漫性大B细胞淋巴瘤	132	Magrolimab plrituximabmabgemcitabinetaboxaliplatinatin	(製膚齋繭製顧膚製衊繭) = 餘製選積衊蓋鏇築鹽範餘鏇襯夢鹹鏇糧顧願鑰 (糧醖網窪積糧淵餘網襯 ) 更多	积极	2024-11-26